Pharmacotherapy of Anal Cancer. - Test2 - elhamkhani - TriplyDB

Pharmacotherapy of Anal Cancer.

Pharmacotherapy of Anal Cancer.

http://www.wikidata.org/entity/Q38647761

about

Pharmacotherapy of Anal Cancer.

http://www.wikidata.org/entity/Q38647761

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Pharmacotherapy of Anal Cancer.

@en

type

label

Pharmacotherapy of Anal Cancer.

@en

prefLabel

Pharmacotherapy of Anal Cancer.

@en

P1433

Q38647761-C94D116A-2ABC-413A-8FE1-C97DF0C15DEC

P1476

Q38647761-9223690D-1714-4424-AB3C-49B03A4F7FF4

P2093

Q38647761-4AA9D25C-DAC4-4DF5-888A-569F193EC297

Q38647761-A87FE0B6-78D7-4AEB-A462-5523071E59EA

P2860

Q38647761-0357E4C1-DA02-49A7-B0EC-F235A1C0362D

Q38647761-0617E7AF-06A4-4324-9E50-5DD54151D825

Q38647761-0E290E1C-07C0-4E4B-9DD8-53BCF5C3EB67

Q38647761-0EF52FA5-A7C7-4DD0-976A-32778073CF91

Q38647761-1AB482D7-EA36-42EE-94EF-AA1CECCE9F21

Q38647761-1C0B7253-51E7-476B-A5A9-DC7EA7DEFDA0

Q38647761-1C71D7BE-AE3F-4E24-9C25-11521B69B3AB

Q38647761-21AC154B-46FE-4416-A6C0-75C015A1C961

Q38647761-21F8F1D3-4FEF-4198-870D-63D7BC14F94A

Q38647761-267E1533-3C9B-4C2F-8736-E8E0659C01CB

P2888

Q38647761-D3C8FAF0-DA1B-49DA-B59C-AA5297C2EAD4

P31

Q38647761-8F356125-5057-4AF8-B6F9-96635F469B4A

P356

Q38647761-99B8731E-51E0-402D-BE31-7C4CD7939F0D

P577

Q38647761-C7B82188-937D-47CC-9733-35065A921DA9

P6179

Q38647761-50A65632-C51A-44A4-92C0-BCF43F67DC80

P698

Q38647761-2BC01DE6-F449-4969-A9FC-DFBDF7359E3D

P921

Q38647761-C89E9149-FCD8-4AF9-957B-86058D0B4741

P356

S40265-017-0792-3

P1433

P1476

Pharmacotherapy of Anal Cancer.

@en

P2093

Cathy Eng

http://www.w3.org/2001/XMLSchema#string

Jane E Rogers

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)

Cancer statistics, 2016

Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels

Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

Improved survival with bevacizumab in advanced cervical cancer

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.

P2888

s40265-017-0792-3

P31

scholarly article

P356

10.1007/S40265-017-0792-3

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090955984

http://www.w3.org/2001/XMLSchema#string

P698

28770514

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy